Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Xuanjing Biotechnology

Request full access

Research and development of innovative small nucleic acid drugs

Suzhou Shi, ChinaFounded 2022Biotech & Life Sciences

About Suzhou Xuanjing Biotechnology

Suzhou Xuanjing Biotechnology, operating as Rigerna, is a clinical-stage biopharmaceutical firm established in 2022, specializing in the development of small interfering RNA (siRNA) therapeutics. The company was founded by Dr. Yuanyu Huang, a distinguished scientist with more than 16 years of academic and industrial experience in the oligonucleotide field. His expertise is underscored by his ranking in the top 0.26% of the “Most Influential Scientists Globally” list, which provides a strong scientific foundation for the company's pursuits. The name 'Rigerna' is a blend of 'Rigel', one of the brightest stars, and 'RNA', reflecting the company's ambition to make significant achievements in the RNAi field.

Rigerna's strategic focus is on addressing unmet medical needs in kidney diseases. The company's business model centers on creating a pipeline of proprietary drug assets by leveraging its in-house technology platforms. These assets are then advanced through clinical development, with the potential for future licensing or commercialization partnerships. The company has secured over $30 million in initial seed and angel financing to support its research and development activities. Its operations are based in Suzhou and Beijing, China.

The core of Rigerna's operations lies in its three proprietary technology platforms: a nucleic acid sequence design and screening platform, a chemical modification platform, and an in-vivo delivery platform. This integrated approach underpins the development of its product pipeline, led by RG002, an siRNA therapeutic candidate for treating IgA nephropathy (IgAN). RG002, which is currently in Phase 1 clinical trials, has shown promise by reducing a key biomarker for IgAN by approximately 60% in non-human primate models. A key differentiator for the company is its novel kidney-targeting delivery platform, which has successfully completed proof-of-concept experiments in non-human primates, demonstrating efficient and targeted delivery of siRNA to the kidneys.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
33.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Apr 2026 $28M $114M Bayland Capital ↗
SEEDOther financing Apr 2025 $14M $55M Guolian Group ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Xuanjing Biotechnology website traffic

Latest recorded traffic for Suzhou Xuanjing Biotechnology is 840 monthly website visits, up 1580% over the last three months.

Latest monthly visits840 3-month web change+1580%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Xuanjing Biotechnology in the Suzhou Shi ecosystem

Live from Dealroom

The Suzhou Xuanjing Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

  • Shanghai Science and Technology Investment
  • Yuanxi Haihe Fund
  • GSR United Capital
  • Trinity Innovation Fund
  • Guolian Group

Series A1 investor entered at this stage

  • Bayland Capital

Other known investors1 additional known investor

  • Beijing Institute of Technology
Employees 5 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Xuanjing Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Xuanjing Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.